Drug intelligence / Profile preview

AB-2 (Algen Biotechnologies)

Development stage: Preclinical
Lead developer: Algen Biotechnologies

Overview

AB-2 is a precision oncology program currently in the discovery and preclinical development stages at Algen Biotechnologies, aimed at treating advanced solid tumors. The program leverages Algen's proprietary AlgenCRISPR and AlgenBrain platforms, which integrate CRISPR gene-editing technology with artificial intelligence to identify novel therapeutic targets within oncogenic pathways such as MYC, RAS, and MYCN. Specifically, AB-2 is designed to target novel RNA components of these pathways. Algen Biotechnologies was established as a spin-out from the laboratory of Nobel Laureate Jennifer Doudna at UC Berkeley. As of late 2025, specific details regarding the drug's molecular modality and exact biological target remain undisclosed.

Beyond the preview

Go deeper on AB-2 (Algen Biotechnologies).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-2 (Algen Biotechnologies).

Explore the full profile